Predict your next investment

Biosplice Therapeutics company logo
HEALTHCARE | Biotechnology
biosplice.com

See what CB Insights has to offer

Founded Year

2008

Stage

Series B | Alive

Total Raised

$561.5M

Last Raised

$120M | 5 mos ago

About Biosplice Therapeutics

Biosplice Therapeutics is a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases. Its scientific platform is based on biological discoveries that govern tissue specialization and enable it to selectively eliminate harmful proteins using small molecules. From the company's foundational discoveries in Wnt pathway modulation to unlocking the broad therapeutic potential of the CLK/DYRK target class, its focus is on the realization of new, potentially curative therapies for patients by selectively reprogramming cellular behavior.

Biosplice Therapeutics Headquarter Location

9360 Towne Centre Drive Suite 160

San Diego, California, 92121,

United States

858-926-2900

Latest Biosplice Therapeutics News

Haisco Enters $140 Million Deal for Osteoarthritis Therapy

Sep 15, 2021

publication date: Sep 15, 2021 Haisco Pharmaceutical of Shannan in-licensed China San Diego 's Biosplice Therapeutics in a $140 million agreement. Lorecivivint, a potential disease-modifying osteoarthritis drug, is a CLK/DYRK kinase inhibitor that modulates the Wnt pathway. It is currently being tested in a US Phase III trial to treat knee osteoarthritis. Biosplice says it has the potential to be the first novel drug therapy for osteoarthritis in nearly 20 years. Haisco will make $20 million in upfront and near-term milestone payments. More details... Stock Symbol: (SHZ: 002653)

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Biosplice Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Biosplice Therapeutics in 1 CB Insights research brief, most recently on Jun 24, 2021.

Expert Collections containing Biosplice Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Biosplice Therapeutics is included in 6 Expert Collections, including Unicorns- Billion Dollar Startups.

U

Unicorns- Billion Dollar Startups

827 items

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

C

Cancer Therapeutics

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

R

Rare Diseases

229 items

R

Regenerative Medicine

1,763 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharmaceuticals

13,989 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Biosplice Therapeutics Patents

Biosplice Therapeutics has filed 112 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • G protein coupled receptors
  • Clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/7/2019

8/3/2021

Transcription factors, Senescence, Rare diseases, Skin care, Cell biology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

8/7/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

8/3/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Transcription factors, Senescence, Rare diseases, Skin care, Cell biology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Biosplice Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Biosplice Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.